Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH – Get Free Report) saw a significant decline in short interest in October. As of October 30th, there was short interest totaling 14,956 shares, a decline of 52.2% from the October 15th total of 31,307 shares. Based on an average daily volume of 27,864 shares, the short-interest ratio is presently 0.5 days. Currently, 0.3% of the shares of the company are short sold.
Wall Street Analyst Weigh In
Separately, Weiss Ratings cut shares of Shuttle Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a research report on Tuesday, November 10th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.
Read Our Latest Report on SHPH
Shuttle Pharmaceuticals Stock Down 6.7%
Shares of Shuttle Pharmaceuticals stock traded down $0.28 on Tuesday, reaching $3.96. The company’s stock had a trading volume of 11,440 shares, compared to its average volume of 722,709. The company has a market capitalization of $18.83 million, a P/E ratio of -0.21 and a beta of -0.04. Shuttle Pharmaceuticals has a 52-week low of $2.58 and a 52-week high of $44.40. The stock has a 50-day moving average price of $4.50 and a 200-day moving average price of $6.33.
Shuttle Pharmaceuticals Company Profile
Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing treatments intended to improve outcomes for patients receiving radiation therapy for cancer. The company is based in Rockville, Maryland. Its lead drug candidate, ropidoxuridine, is an oral prodrug designed to make cancer cells more sensitive to radiation. Shuttle has studied the candidate in combination with radiation therapy, including for patients with glioblastoma, an aggressive form of brain cancer.
Further Reading
- Five stocks we like better than Shuttle Pharmaceuticals
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
Receive News & Ratings for Shuttle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shuttle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
